癌癥腫瘤康復-廣東愛硒健康管理有限公司官網胃癌是消化系統惡性腫瘤之一，據世界衛生組織統計，2020年胃癌分別居全球癌癥發病率和死亡率的第五位和第四位，在我國，胃癌發病率和死亡率分列所有惡性腫瘤的第四位和第三位1。我國胃癌患者確診時多為晚期（II-IV期），約占85%，早期（I期）僅占15.2%2，而晚期胃癌患者的五年總生存率仍不足50%3，其中IV期胃癌僅為9.1%?。但早期胃癌患者行根治性手術切除術后五年OS率超過 90%?，因此手術切除是實現胃癌根治和獲得長期生存的重要手段。然而約有2/3的患者在確診時為不可切除的胃癌?，因此，為該類患者爭取根治性手術機會對提升胃癌總體預后意義重大。近年來，隨著醫學科技進步，腫瘤治療不斷發展以及創新藥物的更迭出新，轉化治療進入大家的視野，旨在通過化療、靶向藥物治療、免疫治療等綜合治療手段，使初始不可切除的腫瘤轉化為R0可切除，從而延長進展期胃癌患者的生存期和提高其生活質量。
開疆拓土
晚期胃癌轉化治療探索之路
天降神兵
信迪利單抗胃癌勢如破竹
圖1 CO-STAR研究中，ORR，DCR，R0轉化率等數據
醫保傳福音惠及更多患者
參考文獻（向上滑動查看）：
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-249.
2. Zeng H, Ran X, An L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health. 2021;6(12):e877-e887.
3. Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555-e567.
4. Li H, Zhang H, Zhang H, Wang Y, Wang X, Hou H. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. Journal of global health. 2022;12:11014.
5. Suzuki H, Oda I, Abe S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer, 2016, 19(1): 198-205
6. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000; 18: 2648-57
7. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Annals of surgery. 1996;224(4):509-520; discussion 520-502.
8. Nakajima T, Ota K, Ishihara S, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Annals of surgical oncology. 1997;4(3):203-208.
9. Al-Batran S-E, Homann N, Pauligk C, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncology. 2017;3(9):1237-1244.
10. Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20(3):517-526.
11. Mitsui Y, Sato Y, Miyamoto H, et al. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemotherapy and Pharmacology. 2015;76(2):375-382.
12. Xu Z, Hu C, Yu J, et al. Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial. Frontiers in pharmacology. 2021;12:642511.
13. Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Annals of Oncology. 2019;30(2):250-258.
14. Chung HC, Bang YJ, C SF, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future oncology (London, England). 2021;17(5):491-501.
15. Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443-1451.
16. Xu J, Jiang H, Pan Y, et al. Abstract CT078: First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial. Cancer Research. 2023;83(8_Supplement):CT078-CT078.
17. Xue Q, Wang B, Wang X, et al. CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC). 2021;39(15_suppl):e16041-e16041.
撰寫：Julius
審校：Dreams
排版：Babel
執行：Faline
本平臺旨在為醫療衛生專業人士傳遞更多醫學信息。本平臺發布的內容，不能以任何方式取代專業的醫療指導，也不應被視為診療建議。如該等信息被用于了解醫學信息以外的目的，本平臺不承擔相關責任。本平臺對發布的內容，并不代表同意其描述和觀點。若涉及版權問題，煩請權利人與我們聯系，我們將盡快處理。
加硒教授微信：623296388，送食療電子書，任選一本